- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01936246
Protein Supplementation in Infants With Brain Injury
To date, few studies have been done regarding nutrition supplementation in infants with brain injury. Therefore, the investigators are proposing to study the effects of protein supplementation in this group of babies. The investigators will recruit 24 infants with brain injury (evidence of hemorrhage, white matter injury, or gray matter injury) admitted to the Cincinnati Children's Hospital Neonatal Intensive Care Unit (NICU) into the study. Upon diagnosis, the investigators will obtain consent from the parents for participation in the study, then randomly assign the baby to one of two groups - an increased protein group and a control group. Both groups of infants will be monitored to ensure no adverse effects occur due to the supplementation.
Protein supplementation will continue for the first 12 months of age. Growth parameters, such as weight, length, and head circumference, will be measured while the infant is the NICU. Head circumference will be measured in the investigators outpatient clinic at three, six, and 12 months of age. At 18-22 months, the infants will be tested for neurodevelopmental outcomes using the Bayley Scales of Infant Development. The investigators hypothesize that infants who receive the additional protein will demonstrate increased head growth and improved neurodevelopmental outcomes.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Infants admitted to the NICU at CCHMC
- Known or suspected brain injury
- Parental consent obtained
- At least 48 hours of age at the time of randomization
Exclusion Criteria:
- Congenital or posthemorrhagic hydrocephalus
- Major congenital brain malformations
- Congenital gastrointestinal malformations or Bell Stage III NEC
- Inborn errors of metabolism
- Chromosomal abnormalities
- Significant cardiac disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Increased protein
Full term infants will be on 4 g/kg/day of protein.
Preterm infants will be on 4.5 g/kg/day of protein until term corrected age.
Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used.
Max protein will be 30 g/day.
Increased protein will be given until 12 months corrected age.
|
Andra namn:
|
|
Inget ingripande: Standard diet
Infants will be given a usual diet.
If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Head circumference
Tidsram: 12 months of age +/- 4 weeks
|
12 months of age +/- 4 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Neurodevelopmental outcome on Bayley Scales of Infant Development
Tidsram: 18-22 months
|
18-22 months
|
|
Weight and length
Tidsram: 3, 6, 12 months of age
|
3, 6, 12 months of age
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Blood urea nitrogen
Tidsram: 10 and 30 days post study initiation
|
10 and 30 days post study initiation
|
|
|
CO2 from renal panel
Tidsram: 10 and 30 days post study initiation
|
To assess for metabolic acidosis
|
10 and 30 days post study initiation
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Stephanie Merhar, MD, Children's Hospital Medical Center, Cincinnati
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CCHMCProtein
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .